CGON (CG Oncology) ROE % Adjusted to Book Value : -3.16% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology ROE % Adjusted to Book Value?

CG Oncology's ROE % for the quarter that ended in Sep. 2024 was -14.99%. CG Oncology's PB Ratio for the quarter that ended in Sep. 2024 was 4.75. CG Oncology's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -3.16%.

CG Oncology ROE % Adjusted to Book Value Historical Data

The historical data trend for CG Oncology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology ROE % Adjusted to Book Value Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial					-	-	-3.50	-3.54	-3.16

Competitive Comparison of CG Oncology's ROE % Adjusted to Book Value

For the Biotechnology subindustry, CG Oncology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CG Oncology's ROE % Adjusted to Book Value falls into.

CG Oncology ROE % Adjusted to Book Value Calculation

CG Oncology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-31.36%	/	N/A
	=	N/A

CG Oncology's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-14.99%	/	4.75
	=	-3.16%

CG Oncology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of CG Oncology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.